Figure 3. Expression of AMPKα, p-AMPKα, PPARγ, ACC-α, p-ACC-α, SREBP-2, and HMGR in liver tissues.

The NAFLD model rats were treated with CHLZT or AICAR for 4 weeks. (A) Western blot detection of AMPKα, p-AMPKα, ACC-α, p-ACC-α, PPARγ, and SREBP-2 (n=4). (B) qRT-PCR detection of PPARγ and SREBP-2 in the different groups (n=3). (C) ELISA for HMGR activity (n=5). **P<0.01; ***P<0.001.